The increased CHK1 activation level we previously observed in UBE2T-overexpressing cells suggested that inhibiting CHK1 might impair UBE2T-induced DDR and radioresistance in HCC cells. This evidence concerns the gene UBE2T and hepatocellular carcinoma.